Patents by Inventor Bolette Hartmann

Bolette Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide dual agonists of GIPR and GLP2R
    Patent number: 11725037
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 15, 2023
    Assignee: University of Copenhagen
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R
    Publication number: 20200392198
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 17, 2020
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • Peptide dual agonists of GIPR and GLP2R
    Patent number: 10774127
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 15, 2020
    Assignee: University of Copenhagen
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS
    Publication number: 20200261543
    Abstract: Provided herewith is the use of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2) for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: October 11, 2018
    Publication date: August 20, 2020
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst, Kirsa Skov-Jeppesen
  • PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R
    Publication number: 20190389924
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: October 12, 2017
    Publication date: December 26, 2019
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • Reduction of parathyroid hormone levels
    Publication number: 20100081622
    Abstract: A method of acutely reducing the plasma level of PTH of a patient having an elevated PTH comprising the administration of a pharmaceutical composition comprising a GLP-2, or a variant, an analogue, or derivative of GLP-2 having the ability to bind and activate a GLP-2 receptor such as GLP-2 1-34.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 1, 2010
    Inventors: Bolette Hartmann, Dennis B. Henriksen